Cell and Gene Supply Chain Services Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Technology (Presence on cloud, Presence on-premises), By Applications (Ordering and scheduling, Sample collection, Logistics, Post treatment follow-up), By End User (Biobank/ cell-bank, Hospitals, Research institutes, Cell therapy labs, Others) Region and Competition, 2020-2030F

Market Overview

The Global Cell and Gene Supply Chain Services Market , valued at USD 1.44 Billion in 2024, is projected to experience a CAGR of 9.85% to reach USD 2.53 Billion by 2030. The Global Cell and Gene Supply Chain Services Market involves the specialized logistics, handling, and controlled storage necessary for transporting sensitive cell and gene therapies, ensuring product integrity from patient sample collection through to administration. The market's growth is predominantly supported by the increasing number of these advanced therapies progressing through clinical trials and receiving regulatory approvals, coupled with significant investments in biopharmaceutical innovation. According to the Alliance for Regenerative Medicine, in 2024, there were nine approvals for cell and gene therapies, marking a record. Furthermore, according to the American Society of Gene and Cell Therapy, in early 2023, over 3,700 cell and gene therapies were in clinical and preclinical development globally.

A significant challenge impeding market expansion is the intricate requirement for establishing and maintaining a robust, globally integrated cryogenic logistics infrastructure. This infrastructure is essential for managing the ultra-cold storage and precise transportation demands inherent to these highly temperature-sensitive therapeutic products. This complexity, combined with evolving regulatory frameworks and the substantial capital outlay required for scaling specialized manufacturing capacities, represents a critical barrier.

Key Market Drivers

Advancements in cell and gene therapy technologies significantly influence the supply chain services market by introducing novel logistical complexities. The evolution of gene editing tools and advanced delivery systems enables precise genetic modifications and expanded therapeutic applications, necessitating highly specialized cold chain management and transport. According to CGTlive®, in May 2024, in its 'Around the Helix: Cell and Gene Therapy Company Updates – May 8, 2024' article, AstraZeneca completed an equity investment agreement with Cellectis, leveraging Cellectis' gene editing technologies and manufacturing capabilities to design up to 10 novel cell and gene therapy products. This directly drives demand for sophisticated logistics. Overall sector investment further underpins this growth; according to the Alliance for Regenerative Medicine, in October 2024, investments in the cell and gene therapy sector reached $10.9 billion in the first half of that year, fueling the pipeline and increasing infrastructure needs.

The growing number of cell and gene therapy clinical trials is a critical market driver, generating demand across all development phases. As investigational therapies progress, specialized collection, processing, cryogenic storage, and distribution of sensitive biological materials become essential. Each trial, particularly for autologous therapies, involves unique logistical challenges in timing, temperature control, and regulatory adherence. This clinical pipeline expansion directly increases reliance on third-party logistics providers with specialized expertise. According to the article 'Cell and Gene Therapy Market Expected To Top US$ 78 Billion', published in November 2024, the number of clinical trials globally dedicated to cell and gene therapy surpassed 2,900 as of mid-2024. This volume intensifies the need for scalable and agile supply chain services managing complex operations.

Download Free Sample Report

Key Market Challenges

The intricate requirement for establishing and maintaining a robust, globally integrated cryogenic logistics infrastructure presents a significant impediment to the Global Cell and Gene Supply Chain Services Market. These advanced therapies demand ultra-cold storage and precise, uninterrupted temperature-controlled transportation to preserve product integrity from patient sample collection through final administration. The technical complexity and specialized equipment necessary for such rigorous cold chain management across diverse geographic regions create substantial operational hurdles for service providers.

This infrastructure challenge directly hampers market growth due to the considerable financial burden involved. Developing and scaling these highly specialized capabilities requires substantial capital outlay for advanced freezers, monitoring systems, and specialized transport vehicles capable of maintaining ultra-low temperatures, often below -150°C. According to the Alliance for Regenerative Medicine, investments in the cell and gene therapy sector reached $15.2 billion in 2024, highlighting the significant capital flow into the broader industry. However, the specific, high costs associated with building out a reliable global cryogenic supply chain divert resources and deter new entrants, thus limiting the expansion of essential services required to support the rapidly increasing pipeline of cell and gene therapies entering clinical development and commercialization.

Key Market Trends

The two most significant trends driving growth in the Global Cell and Gene Supply Chain Services Market are Enhanced Digital Traceability and Supply Chain Optimization, and Decentralized Manufacturing and Regional Hub Development. These trends address critical needs for efficiency, risk reduction, and accessibility in the complex logistics of cell and gene therapies.

Enhanced Digital Traceability and Supply Chain Optimization focuses on leveraging advanced technologies to achieve real-time visibility and control across the entire supply chain. Given the personalized and time-sensitive nature of cell and gene therapies, accurate tracking of materials from patient sample collection to administration is paramount for maintaining product integrity and patient safety. Digitalization and real-time tracking technologies can significantly minimize supply chain risks by enhancing product visibility throughout the value chain. According to PwC, in November 2023, digitalization and analytics, artificial intelligence, and blockchain were highlighted as key technologies for enhancing the efficiency, quality, traceability, and security of the cell and gene therapy supply chain. This improved traceability also supports efficient contingency planning in the event of deviations, such as temperature excursions, which are critical for therapies often requiring ultra-cold storage.

Decentralized Manufacturing and Regional Hub Development represents a strategic shift towards localizing production and storage facilities to overcome logistical challenges inherent in a globalized supply chain. This trend mitigates risks associated with long-distance transportation and reduces vein-to-vein times, especially for autologous therapies where the patient's own cells are used. With a decentralized model, using multiple smaller facilities located near treatment centers can simplify the complex supply chain and potentially eliminate the need for cryopreservation during transportation, thereby reducing costs and improving patient access. The Alliance for Regenerative Medicine predicts that over 20 new gene therapies will gain regulatory approval by 2025, further increasing the demand for decentralized and point-of-care manufacturing solutions. This localized approach fosters closer communication between manufacturers, healthcare professionals, and patients, enabling better coordination and increased treatment slot availability.

Segmental Insights

The Logistics segment is a primary growth driver within the Global Cell and Gene Supply Chain Services Market, rapidly expanding due to the unique demands of these advanced therapies. This growth is propelled by the critical need for meticulous ultra-cold chain management and precise temperature control, essential for preserving the integrity and short viability of delicate, often patient-specific products from collection to administration. Moreover, stringent regulatory guidelines from bodies such as the FDA and EMA mandate specialized handling, real-time tracking, and robust chain of identity and custody protocols throughout the complex vein-to-vein logistics process, ensuring the safe and compliant delivery of these invaluable treatments to patients globally.

Regional Insights

North America dominates the global cell and gene supply chain services market due to its highly developed biotechnology ecosystem and substantial investments in research and development. The region benefits from a robust regulatory environment, exemplified by the U. S. Food and Drug Administration (FDA), which provides clear guidelines and accelerated approval pathways for innovative cell and gene therapies. This supportive framework, coupled with advanced manufacturing capabilities and strong intellectual property protection, fosters a significant number of clinical trials and commercialization efforts. The increasing demand for personalized medicine and the high prevalence of chronic diseases further drive the need for specialized supply chain services in the region.

Recent Developments

• In October 2025, Peli BioThermal, a global leader in temperature-controlled logistics solutions, acquired Evo from BioLife Solutions. This acquisition significantly expanded Peli BioThermal’s portfolio, particularly within the pharmaceutical value chain for cell and gene therapies. The Evo portfolio includes specialized cryogenic shippers and the evoIS® technology platform, designed to meet the stringent requirements of the rapidly expanding cell and gene therapy sector. This strategic move aims to strengthen Peli BioThermal’s ability to provide a comprehensive range of cold chain solutions, offering enhanced options to existing clients and fostering new partnerships in the biopharmaceutical and clinical supply sectors.

• In March 2025, DHL Group acquired CRYOPDP, a specialized courier primarily focused on clinical trials, biopharma, and cell and gene therapies. This acquisition was part of DHL's strategy to strengthen its Pharma Specialized Network and expand its offerings in the rapidly growing life sciences and healthcare sector. Concurrently, DHL also announced a strategic partnership with Cryoport, Inc., bringing together DHL's global health logistics capabilities with Cryoport's expertise in specialized solutions for temperature-sensitive products. This initiative enhances their collective ability to provide integrated end-to-end supply chain solutions for cell and gene therapies worldwide.

• In November 2024, TrakCel, a provider of integrated cell and gene therapy orchestration solutions, announced that its OCELLOS platform was selected to support five of the seven autologous or matched allogeneic cell therapy products anticipated for approval that year. The OCELLOS platform, built on Salesforce, offers a unique therapy process that connects base modules and configurable forms, providing real-time visibility into each personalized therapy's journey through the supply chain. This adoption is crucial for manufacturers to successfully launch FDA-approved products and for Approved Treatment Centers to safely and efficiently administer cell and gene therapies, enhancing supply chain efficiency and collaboration.

• In June 2024, Cryoport, Inc., a global provider of supply chain solutions for life sciences, and Minaris Regenerative Medicine Co., Ltd., a contract development and manufacturing organization for cell and gene therapies, announced a strategic partnership. This collaboration aims to deliver integrated logistics and manufacturing services for regenerative medicine products, from initial cell and tissue collection through to patient delivery. The initiative supports pharmaceutical and biotechnology companies in advancing cell and gene therapies globally by combining Cryoport's logistics expertise with Minaris' manufacturing capabilities. This development addresses the complex supply chain requirements of the growing regenerative medicine industry, ensuring seamless support for new therapeutic modalities.

Key Market Players

• Biocair International Limited
• Arvato SE
• Associated Couriers, LLC.
• TrakCel Limited
• Parkoursc Inc.
• DHL
• McKesson Corporation
• Almac Group Limited
• Catalent Inc.
• Biostor Ltd.

Report Scope:

In this report, the Global Cell and Gene Supply Chain Services Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• Cell and Gene Supply Chain Services Market , By Technology:

o   Presence on cloud

o   Presence on-premises

• Cell and Gene Supply Chain Services Market , By Applications:

o   Ordering and scheduling

o   Sample collection

o   Logistics

o   Post treatment follow-up

• Cell and Gene Supply Chain Services Market , By End-User:

o   Biobank/ cell-bank

o   Hospitals

o   Research institutes

o   Cell therapy labs

o   Others

• Cell and Gene Supply Chain Services Market , By Region:

o   North America

§  United States

§  Canada

§  Mexico

o   Europe

§  France

§  United Kingdom

§  Italy

§  Germany

§  Spain

o   Asia Pacific

§  China

§  India

§  Japan

§  Australia

§  South Korea

o   South America

§  Brazil

§  Argentina

§  Colombia

o   Middle East & Africa

§  South Africa

§  Saudi Arabia

§  UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies presents in the Global Cell and Gene Supply Chain Services Market .

Available Customizations:

Global Cell and Gene Supply Chain Services Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Global Cell and Gene Supply Chain Services Market is an upcoming report to be released soon. If you wish an early delivery of this report or want to confirm the date of release, please contact us at [email protected]